Fazaclo

Known as: CLOZAPINE (FAZACLO) 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
  • 2012
BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR… (More)
  • figure 1
  • table 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2012
2012
OBJECTIVE To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2008
2008
AbstractBackground: This study compared the bioequivalence of FazaClo® (clozapine orally disintegrating tablets) 100 mg to… (More)
Is this relevant?
Review
2007
Review
2007
Compared with the general population, individuals with schizophrenia demonstrate an increased prevalence of obesity. While most… (More)
  • table 1
  • table 2
Is this relevant?
2007
2007
OBJECTIVE Interventions improving adherence to antipsychotic medication are needed. The present study examined the effects on… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND The main objective was to assess the efficacy of a weight management program designed for outpatients taking… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Review
2005
Review
2005
Patients with schizophrenia are at significantly increased risk for infection with human immunodeficiency virus (HIV), hepatitis… (More)
Is this relevant?